Encelion LLC v. Oura Health Oy: Pulse Sensor Patent Suit Dismissed Without Prejudice
Encelion LLC, holder of US11471072B2 covering pulse sensor systems and methods, filed an infringement action against smart ring maker Oura Health Oy in the Eastern District of Texas. The case closed just 34 days after filing when Encelion voluntarily dismissed without prejudice — leaving the door open for refiling.
A 34-day E.D. Texas pulse sensor suit ends before it begins
On November 6, 2025, Encelion LLC filed a patent infringement complaint against Oura Health Oy in the United States District Court for the Eastern District of Texas (Case No. 2:25-cv-01107). The action asserted US11471072B2, which covers a pulse sensor, system, and method for using a pulse sensor — technology directly relevant to Oura’s wearable smart ring product line, which relies on photoplethysmography and related biosensing methods.
On December 10, 2025 — just 34 days after filing — Encelion filed a Notice of Voluntary Dismissal Without Prejudice pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure. The court accepted and acknowledged the notice, dismissed all pending claims without prejudice, and directed the clerk to close the case. No fees, costs, or substantive rulings were entered against either party.
The 34-day duration is notably brief and suggests the dismissal occurred before Oura Health had filed an answer or a motion for summary judgment, which is the procedural window in which a plaintiff may dismiss as of right under Rule 41(a)(1)(A)(i). The public record does not disclose whether the parties reached a licensing arrangement, settlement in principle, or whether Encelion intends to refile. The without-prejudice designation keeps all options open for the patent holder.
Filing to Dismissed without Prejudice in 34 days
34 days — resolved before any substantive motion practice or claim construction
Dismissed without prejudice: what the voluntary exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff’s right to dismiss before answer
Under Federal Rule of Civil Procedure 41(a)(1)(A)(i), a plaintiff may voluntarily dismiss a case without a court order at any time before the defendant serves an answer or a motion for summary judgment. This is an automatic right — no judicial approval is required, though the court here formally accepted and acknowledged the notice. The dismissal carries no merits determination and imposes no preclusive effect.
No merits rulingWithout prejudice: Encelion retains the right to refile
A dismissal without prejudice does not extinguish Encelion’s claims. The patent — US11471072B2 — remains in force, and Encelion may reassert it against Oura Health or other parties in a future action. The public record does not disclose whether a licensing agreement, term sheet, or other resolution was reached. The strategic optionality preserved here is significant: the plaintiff has not conceded validity, infringement, or claim scope.
Claims preservedOura Health exits without a finding — but exposure persists
Oura Health Oy obtains no invalidity ruling, no non-infringement finding, and no fee award from this dismissal. The threat posed by US11471072B2 remains legally unresolved. If no license was negotiated, Oura faces the possibility of a refiled action, potentially in the same or a different venue. Absent a covenant not to sue, Oura’s legal exposure to this patent is substantively unchanged by the dismissal.
No preclusive effectWearable biosensor sector: patent risk on pulse-sensing IP remains live
US11471072B2 covers pulse sensor systems and methods — a foundational technology in the growing wearable health-monitoring market. The without-prejudice dismissal signals that this patent remains a viable enforcement asset. Companies developing or selling photoplethysmography-based or optical pulse-sensing wearables should treat this patent as an active risk vector. The Eastern District of Texas remains a favored venue for patent assertion entities targeting technology companies.
Active IP riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Encelion LLC | Company | Patent assertion entity — holder of US11471072B2 covering pulse sensor systemsSearch in Eureka ↗ |
| Defendant | Oura Health Oy | Individual | Oura Health Oy — Finnish maker of the Oura Ring wearable biosensing smart ringSearch in Eureka ↗ |
| Plaintiff counsel | Isaac Phillip Rabicoff | Attorney | Counsel for Encelion LLCSearch in Eureka ↗ |
| Plaintiff law firm | Rabicoff Law LLC | Law Firm | Representing Encelion LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Texas Eastern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order tracks the language of Encelion’s own notice closely, confirming the dismissal is without prejudice and grounded in Rule 41(a)(1)(A)(i) — a procedural mechanism that requires no judicial discretion once properly invoked before an answer is filed. The denial of all other relief as moot confirms no substantive rulings were made on infringement, validity, or claim scope. Neither party’s legal position on the merits is altered by this order.
US11471072B2 — Pulse sensor, system, and method for using a pulse sensor
US11471072B2 protects a pulse sensor, the system architecture in which it operates, and the methods for using such a sensor to capture physiological data. The application number US17/206065 places the filing in the period when wearable health monitoring was accelerating rapidly, with optical heart-rate and SpO2 sensing becoming standard in consumer devices. The patent’s claims — covering both apparatus and method — give the holder broad enforcement options across hardware manufacturers, software platform providers, and OEM integrators.
In the context of the wearable biosensor market, US11471072B2 sits at the intersection of consumer health tech and medical-grade monitoring — a space attracting significant R&D investment from companies including Oura, Apple, Samsung, Garmin, and Fitbit. A patent covering a pulse sensor system and method of use can implicate multiple product layers: the sensor hardware, signal processing firmware, and health analytics software. Companies active in this space should map their implementations against the issued claims before expanding product lines.
Should you run an FTO analysis against US11471072B2?
Any company developing, manufacturing, or distributing wearable devices that incorporate pulse sensing — including smart rings, fitness bands, medical-grade patches, and smartwatches — should evaluate their exposure to US11471072B2. The patent covers both the sensor system and the method of use, meaning that even if a company designs around the hardware claims, method claims may still be implicated by how the device operates in use. This case names a market-leading smart ring maker, signalling that assertion against premium wearable brands is a viable strategy.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map product functionality against the full claim set of US11471072B2, identify related family members and continuation applications, and benchmark exposure across the pulse-sensing patent landscape. Eureka can surface prosecution history, claim amendments, and prior art references that may inform design-around strategies — reducing litigation risk before a product reaches market.
Run a freedom-to-operate analysis on US11471072B2 to assess your product’s exposure
Run FTO in Eureka →Similar pulse sensor and wearable biosensor patent cases in E.D. Texas
Explore related infringement actions involving pulse sensing, photoplethysmography, and wearable biosensor patents filed in the Eastern District of Texas.
What this case signals for the wearable biosensor IP landscape
A rapid voluntary dismissal in E.D. Texas rarely signals defeat — it more often signals negotiation, leverage, or strategic repositioning by the patent holder.
Early dismissal in E.D. Texas typically signals negotiation, not surrender
A 34-day lifecycle — ending before the defendant even filed an answer — is consistent with one of two scenarios: a licensing arrangement was reached quietly, or the plaintiff is repositioning for a stronger refiling. Either way, US11471072B2 remains a live enforcement asset. Competitors and adjacent technology companies should not interpret this dismissal as a resolution of the underlying IP dispute.
Oura Health’s pulse-sensing technology is now a documented litigation target
Even without a merits ruling, the act of filing places Oura’s photoplethysmography and pulse-sensing implementation on the public litigation record. This may attract attention from other patent holders monitoring the space. Oura — and companies building similar wearable biosensor functionality — should conduct proactive freedom-to-operate analysis against pulse-sensor patent families, including US11471072B2 and its continuations.
Encelion v Oura — key questions answered
The dismissal without prejudice means all of Encelion’s claims were ended without any ruling on the merits. Encelion retains the right to refile the same claims against Oura Health or other parties. No finding was made on infringement, validity, or claim scope, and no fees or costs were awarded to either party.
Encelion asserted US11471072B2, titled and covering a pulse sensor, system, and method for using a pulse sensor. The underlying application number is US17/206065. The patent covers both apparatus and method claims relevant to wearable pulse-sensing technology, which is core to Oura’s smart ring product line.
The public record does not disclose the reason for the rapid dismissal. Under Rule 41(a)(1)(A)(i), a plaintiff may dismiss as of right before the defendant answers or moves for summary judgment. The 34-day timeline is consistent with either an early-stage licensing negotiation, a settlement in principle, or a strategic decision to refile. No adverse ruling or substantive motion preceded the dismissal.
Yes. Because the dismissal was entered without prejudice, Encelion’s claims are not extinguished and may be reasserted. Encelion could refile in the Eastern District of Texas or another venue. The patent US11471072B2 remains in force and its enforceability is unaffected by the dismissal.
US11471072B2 covers a pulse sensor system and method of use — technology embedded in smart rings, fitness trackers, and health-monitoring wearables. The case against Oura Health signals that the patent holder is willing to assert these claims against premium wearable brands. Companies commercialising optical pulse sensing or PPG-based health monitoring should conduct freedom-to-operate analysis against this patent and its related family members.
PatSnap Eureka searches patents and litigation data to answer instantly.